Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The recommended antiplatelet treatment regimen for patients affected by acute coronary
syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI) consists in the
combination of aspirin and a P2Y12 receptor inhibitor. More potent P2Y12 receptor inhibitors,
such as ticagrelor, have been developed which are associated with less response variability
than clopidogrel and better clinical outcomes. Ticagrelor use has increased significantly
because of its more expanded Food and Drug Administration (FDA) indications compared with
prasugrel. However, despite the evidence for sustained efficacy and safety, many physicians
limit treatment duration with ticagrelor to the early phases following an ACS mostly due to
cost issues and concerns about increased bleeding. Therefore, it is very common in clinical
practice to switch patients while on maintenance dosing (MD) with ticagrelor to treatment
with clopidogrel. However, the pharmacodynamic (PD) effects of switching from ticagrelor to
clopidogrel remain unknown. Therefore, the aim of this investigation is to evaluate the PD
effects of switching from ticagrelor to clopidogrel.